Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
Asserts CSG has acted in bad faith, ignoring obligations as strategic partner for Spotfire® software
CSG is refusing to honor its contractual obligations with Revvity as a strategic partner, including violating the terms of its agreements with Revvity for its TIBCO Spotfire® software. In addition, CSG is interfering in Revvity’s customer relationships by directly contacting Revvity’s customers, as well as engaging in willful misconduct by marketing the Spotfire products in Revvity’s exclusive markets.
For over a decade, Revvity has been the exclusive provider of Spotfire to the research and clinical markets.
“Continuing to serve our customers remains our top priority, and we will take all actions necessary to enforce our rights and CSG’s obligations in this regard,” stated
The Company is reaffirming its 2024 full year guidance of total revenue of
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320557979/en/
Investor Relations:
steve.willoughby@revvity.com
Corporate Communications:
fara.goldberg@revvity.com
Source: Revvity